Início › Leucemia Linfoblástica Aguda › Illinois
Ensaios clínicos de Leucemia Linfoblástica Aguda em Illinois
20 estudos para Leucemia Linfoblástica Aguda estão buscando participantes em locais em Illinois.
Cidades em Illinois
Texto oficial do estudo (Inglês)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- e mais 54
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- The University of Chicago Medical Center, Chicago
RecrutandoFase 1/2
30 Days · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT04065399The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- e mais 6
RecrutandoFase 1/2
Até 22 anos · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04726241Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecrutandoFase 2
Idades de 7 a 25 · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT05082519A Study of CTD402 in T-ALL/LBL Patients
- University of Chicago, Chicago
RecrutandoFase 1/2
Idades 1 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT07070219Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- The University of Chicago, Chicago
RecrutandoEstudo observacional
1 Day – 17 Years · Todos os sexos · Atualizado em 14 de ago. de 2026 · NCT06274788Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Research Site, Decatur
RecrutandoFase 1/2
Idades 16 e acima · Todos os sexos · Atualizado em 20 de jul. de 2026 · NCT07155226Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 13 de jul. de 2026 · NCT07109219Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Recrutando
Idades 15 e acima · Todos os sexos · Atualizado em 10 de jul. de 2026 · NCT06446661A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- e mais 3
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT01351545Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago
Recrutando
Idades 14 e acima · Todos os sexos · Atualizado em 30 de jun. de 2026 · NCT03932903Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- University of Chicago Medical Center, Chicago
RecrutandoFase 1
Idades de 18 a 39 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT03571321Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
- University of Chicago Medical Center, Chicago
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 5 de jun. de 2026 · NCT04747912Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Lurie Children's Hospital-Chicago, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- Saint Jude Midwest Affiliate, Peoria
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 18 de mai. de 2026 · NCT01790152Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
RecrutandoFase 1
Idades 13 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT04771572A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 24 de mar. de 2026 · NCT04988555A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 18 de mar. de 2026 · NCT06207123Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
RecrutandoFase 2
Idades de 18 a 54 · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06918431Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
RecrutandoFase 1
Idades de 1 a 40 · Todos os sexos · Atualizado em 12 de mar. de 2026 · NCT05292664Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RecrutandoFase 1
Idades de 1 a 21 · Todos os sexos · Atualizado em 6 de dez. de 2024 · NCT05476770Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.